|
See related Clopidogrel Actavis film-coated tab information |
|
|
|
Manufacturer |
Actavis |
|
Distributor |
Hong Kong: Zuellig/Macau: Firma Chun Cheong |
|
Contents |
Clopidogrel bisulfate |
|
Indications |
Prevention of atherothrombotic events in MI (<35 days), ischaemic stroke (7 days-6 mth), established peripheral arterial disease; non-ST segment elevation acute coronary syndrome (unstable angina or non-Q wave MI) in combination w/ aspirin. |
|
Dosage |
75 mg once daily. Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q wave MI) Loading dose: 300 mg as a single dose. Maintenance: 75 mg once daily w/ aspirin 75-325 mg daily. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Active pathological bleeding (eg gastric ulcer or intracranialhemorrhage); severe hepatic failure. Childn. Pregnancy & lactation. |
|
Special Precautions |
Patient w/ high risk of increased bleeding in trauma, surgery or other pathological states. Discontinue 5 days pre-op. Renal impairment. |
|
Adverse Drug Reactions |
Bleeding, heartburn, warmth, abdominal pains, diarrhea.
View ADR Monitoring Form |
|
Drug Interactions |
Warfarin, glycoprotein IIb/IIIa inhibitors, aspirin, NSAIDs.
View more drug interactions with Clopidogrel Actavis |
|
Pregnancy Category (US FDA) |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
